Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson bought 8,183 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $22.13 per share, for a total transaction of $181,089.79. Following the completion of the transaction, the chief financial officer owned 8,183 shares in the company, valued at approximately $181,089.79. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Sensei Biotherapeutics Stock Performance
Shares of NASDAQ:FTH opened at $24.67 on Friday. Sensei Biotherapeutics, Inc. has a one year low of $6.32 and a one year high of $36.76.
Analyst Upgrades and Downgrades
A number of research firms have commented on FTH. BTIG Research raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. HC Wainwright initiated coverage on Sensei Biotherapeutics in a research note on Monday. They issued a “buy” rating and a $60.00 price target on the stock. Finally, Weiss Ratings began coverage on Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.
Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
